Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204537 | 0.88 | KDM4E (0.46) | CHRM3BCHEMAOBACHEHDAC3 | |
| SCHEMBL6225945 | 0.82 | BCHE (0.48) | CHRM3BCHEMAOBACHEHDAC3 | |
| SCHEMBL6224442 | 0.80 | BCHE (0.48) | CHRM3BCHEMAOBACHEHDAC3 | |
| SCHEMBL6664439 | 0.78 | CHRM3 (0.56) | CHRM3ACHE | |
| SCHEMBL6420126 | 0.77 | CHRM3 (0.56) | CHRM3BCHEMAOBACHECHRM2 | |
| SCHEMBL3788242 | 0.73 | CPB1 (0.42) | — | |
| SCHEMBL830217 | 0.73 | USP30 (0.45) | CHRM3 | |
| SCHEMBL6663459 | 0.72 | CHRM3 (0.58) | CHRM3ACHE | |
| SCHEMBL16468054 | 0.71 | HIF1A (0.41) | — | |
| SCHEMBL1058987 | 0.71 | LIPE (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885BCHE 97/4885MAOB 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.